CN1468600A - Preparation method of doxofylline glucose injection - Google Patents
Preparation method of doxofylline glucose injection Download PDFInfo
- Publication number
- CN1468600A CN1468600A CNA021326193A CN02132619A CN1468600A CN 1468600 A CN1468600 A CN 1468600A CN A021326193 A CNA021326193 A CN A021326193A CN 02132619 A CN02132619 A CN 02132619A CN 1468600 A CN1468600 A CN 1468600A
- Authority
- CN
- China
- Prior art keywords
- injection
- doxofylline
- glucose
- water
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 16
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229960004483 doxofylline Drugs 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229940093181 glucose injection Drugs 0.000 title claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 229940090044 injection Drugs 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000009287 sand filtration Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical group NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 229940013402 aminophylline injection Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention mainly relates to a prescription of a bronchodilator doxofylline glucose injection and a preparation method thereof, which is characterized in that doxofylline and glucose are dissolved by injection water, the pH value is adjusted by inorganic acid, and the injection is prepared by the steps of filtration, sterilization and the like.
Description
The present invention relates to a kind of preparation method for the treatment of asthma new drug dosotheophylline glucose injection.
Asthma is one of three big diseases of long-term hazards health, necessary intravenous injection bronchodilator rapidly when serious asthma attack, the used for intravenous injection bronchodilator is the indispensable medicine of treatment severe asthma, clinical just widely used bronchodilator is an aminophylline injection at present, these product not only local irritation are big, and toxicity is very big, drug level is too high or drip velocity is too fast, can strong excited heart, cause dizziness, cardiopalmus, arrhythmia, the blood pressure sharp fall, severe patient can cause convulsions, for the old man, the child, darling renal function obstacle and hyperthyroidism person more need careful usefulness.And anti-to breathe heavily the Zhichuan of new drug dosotheophylline glucose injection effective, and toxic and side effects is low, and blood vessel is not had local irritation, and no anaphylaxis and hemolytic need not dilute directly to import and bring into play anti-asthmatic action in patient's body rapidly, have great clinical use value.
Along with improving constantly of clinical treatment development of technology and people's lives, transfusion class pharmaceutical requirements increases rapidly, but China's transfusion kind is few, especially therapeutic type transfusion famine, can not satisfy clinical growing needs far away, medical institutions are according to the treatment needs, have to some injections are added in the transfusion and use, this method is not only operated inconvenience, the quality time that needs during waste patient first aid, and in process for preparation, occur easily polluting, there is very big malpractice hidden danger, therefore the invention of doxofylline glucose injection has great importance to stability and the safety that improves medicine.
Preparation technology of the present invention is simple, and cost is low, is easy to control of quality.
Now preparation method of the present invention is described in down:
Prescription:
Doxofylline 20-50g
Glucose 500-1000g
Mineral acid 5-100ml
Water for injection adds to 4000-10000ml
The step of preparation is:
1. take by weighing the glucose of recipe quantity, earlier glucose is added the injection water and make the solution that concentration is about 50-60%, to 3.8-4.0, the injection active carbon that adds 0.1-2.0% boiled 15-20 minute with the mineral acid adjust pH, filter with the sand filtration rod while hot, filtrate adds the injection water and suitably dilutes.
2. doxofylline is slowly added, stir and make dissolving.Transfer pH to 3.0-6.0 with mineral acid, be diluted to prescribed volume with water for injection at last.
3. clarify with filtering with microporous membrane to medicinal liquid, embedding is sealed in the vial of washing and sterilizing after the passed examination.
4. the vial of sealing is put in the sterilization cabinet, 115 ℃ of 20-50 minute pressure sterilizings, leak detection, packing is promptly.
Embodiment
Doxofylline 30g
Glucose 500g
Hydrochloric acid 30ml
Water for injection adds to 10000ml
The step of preparation is:
1. take by weighing the glucose of recipe quantity, earlier glucose is added injection water water and make the solution that concentration is about 50-60%, to 3.8-4.0, the injection active carbon that adds 0.1-2.0% boiled 20 minutes with the hydrochloric acid adjust pH, filter with the sand filtration rod while hot, filtrate adds the injection water and suitably dilutes.
2. doxofylline is slowly added, stir and make dissolving.Transfer pH to 4.0 with hydrochloric acid, be diluted to 10000ml with water for injection at last.
3. clarify with filtering with microporous membrane to medicinal liquid, embedding is sealed in the vial of washing and sterilizing after the passed examination.
4. the infusion bottle of sealing is put in the sterilization cabinet, 115 ℃ of 30 minutes pressure sterilizings, leak detection, packing is promptly.
Claims (2)
1. the preparation method of doxofylline glucose injection, it is characterized in that: this product is made by the following step
(1). glucose is added water make the solution that concentration is about 50-60%, to 3.8-4.0, the injection active carbon that adds 0.1-2.0% boiled 15-20 minute with the mineral acid adjust pH, filtered with the sand filtration rod while hot, and filtrate adds the injection water and suitably dilutes.
(2). doxofylline is slowly added, stir and make dissolving.Transfer pH to 3.0-6.0 with mineral acid, be diluted to 10000ml with water for injection at last.
(3). clarify with filtering with microporous membrane to medicinal liquid, embedding is sealed in the vial of washing and sterilizing after the passed examination.
(4). the vial of sealing is put in the sterilization cabinet, 115 ℃ of 30 minutes pressure sterilizings, leak detection, packing is promptly.
2. according to the preparation method of claim 1, the prescription of wherein said each component is:
Doxofylline 20-50g
Glucose 500-1000g
Mineral acid 5-100ml
Water for injection adds to 4000-10000ml
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021326193A CN1468600A (en) | 2002-07-18 | 2002-07-18 | Preparation method of doxofylline glucose injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021326193A CN1468600A (en) | 2002-07-18 | 2002-07-18 | Preparation method of doxofylline glucose injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1468600A true CN1468600A (en) | 2004-01-21 |
Family
ID=34145253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021326193A Pending CN1468600A (en) | 2002-07-18 | 2002-07-18 | Preparation method of doxofylline glucose injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1468600A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953803A (en) * | 2010-09-02 | 2011-01-26 | 天津市铭泰医药科技有限公司 | Preparation method of small-volume doxofylline freeze-dried powder injection as well as product and device thereof |
| CN101647776B (en) * | 2009-09-02 | 2011-04-20 | 吴光彦 | Doxofylline venous injection with small volume as well as preparation method and quality control method thereof |
| CN103159769A (en) * | 2013-04-01 | 2013-06-19 | 湖北美林药业有限公司 | Doxofylline compound and medicine composition thereof |
| CN103848831A (en) * | 2014-03-18 | 2014-06-11 | 山东罗欣药业股份有限公司 | Doxofylline compound and pharmaceutical composition thereof |
| CN109966246A (en) * | 2019-04-16 | 2019-07-05 | 周锡明 | A kind of doxofylline injection type composition |
-
2002
- 2002-07-18 CN CNA021326193A patent/CN1468600A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647776B (en) * | 2009-09-02 | 2011-04-20 | 吴光彦 | Doxofylline venous injection with small volume as well as preparation method and quality control method thereof |
| CN101953803A (en) * | 2010-09-02 | 2011-01-26 | 天津市铭泰医药科技有限公司 | Preparation method of small-volume doxofylline freeze-dried powder injection as well as product and device thereof |
| CN103159769A (en) * | 2013-04-01 | 2013-06-19 | 湖北美林药业有限公司 | Doxofylline compound and medicine composition thereof |
| CN103159769B (en) * | 2013-04-01 | 2015-03-11 | 湖北美林药业有限公司 | Doxofylline compound and medicine composition thereof |
| CN103848831A (en) * | 2014-03-18 | 2014-06-11 | 山东罗欣药业股份有限公司 | Doxofylline compound and pharmaceutical composition thereof |
| CN103848831B (en) * | 2014-03-18 | 2015-03-11 | 山东罗欣药业集团股份有限公司 | Doxofylline compound and pharmaceutical composition thereof |
| CN109966246A (en) * | 2019-04-16 | 2019-07-05 | 周锡明 | A kind of doxofylline injection type composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1465688B9 (en) | Bicarbonate-based solutions for dialysis therapies | |
| AU754537B2 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| CN101209344B (en) | Application of hyperosmotic fluid composition in preparing medicament for improving wound healing | |
| NO320743B1 (en) | Aqueous moxibloxacin formulation with saline, and process and combination preparation thereof | |
| MXPA06000973A (en) | Dialysis solutions with reduced levels of glucose degradation products. | |
| CN107412152B (en) | Dexmedetomidine hydrochloride injection composition | |
| CN1044559C (en) | "Ailing" anticancer injection | |
| WO2022222630A1 (en) | Multiple electrolytes injection and preparation method therefor | |
| CN1468600A (en) | Preparation method of doxofylline glucose injection | |
| CN101190214B (en) | Paclitaxel injection and preparation method thereof | |
| CN103932981A (en) | Heparin sodium tube-sealing injection | |
| CN110179888A (en) | A kind of arcotic oral solution and preparation method thereof for gastric operation | |
| CN106109401A (en) | A kind of high-purity tranexamic acid injection and preparation method thereof and in the application of cardiac operation Perioperation of Cardiopulmonary Bypass Surgery indication | |
| CN102949339A (en) | Rocuronium bromide-containing injection | |
| CN1287851C (en) | Ossotide sodium chloride injection and its preparing process | |
| CN104922060B (en) | A kind of Ibandronate composition | |
| CN1190205C (en) | Diemailing injection and its preparing process | |
| CN1244403A (en) | Preparation of isotomic Shengmei injecta | |
| CN102240261A (en) | Preparation method and medicinal purpose of glucomannan injection | |
| CN115811988A (en) | Blood purification molecule concentrate and preparation method and application thereof | |
| CN111603479A (en) | Blood purification concentrate | |
| CN1194831A (en) | Ribavirin large infusion series preparation | |
| CN110693822A (en) | Ibuprofen injection and preparation method thereof | |
| CN104721223B (en) | A kind of injection pharmaceutical composition of compound electrolyte and preparation method thereof | |
| CN108926703A (en) | Ossotide glucose injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |